A phase 3, open-label, crossover study to evaluate the efficacy and safety of human insulin inhalation powder (HIIP) compared with once-daily insulin glargine in insulin-naive patients with type 2 diabetes mellitus on oral agents

Trial Profile

A phase 3, open-label, crossover study to evaluate the efficacy and safety of human insulin inhalation powder (HIIP) compared with once-daily insulin glargine in insulin-naive patients with type 2 diabetes mellitus on oral agents

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2008

At a glance

  • Drugs Insulin (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jul 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
    • 16 Nov 2007 Status change from recruiting to in progress, in accordance with clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top